Jalandhar Online

Chronic Wounds Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Chronic Wounds Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 02
18:06 2021
Chronic Wounds Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
DelveInsight’s “Chronic Wounds Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Chronic Wounds pipeline landscapes. It comprises Chronic Wounds pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chronic Wounds therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chronic Wounds pipeline products.

DelveInsight’s Chronic Wounds Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the Chronic Wounds pipeline landscapes. It comprises Chronic Wounds pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chronic Wounds therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chronic Wounds pipeline products.     

Some of the key takeaways of the Chronic Wounds Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Anterogen, ViroMed BioPharma, Novalead Pharma, Oneness Biotech, MediWound, Tissue Tech/Amniox Medical, Charsire Biotechnology, Energenesis Biomedical, etc., are developing therapies for the treatment of Chronic Wounds.

  • Emerging therapies such as ALLO-ASC-DFU, Engensis, Galnobax, ON101, EscharEx, TTAX01, CSTC1, ENERGI-F703,are expected to have a significant impact on the  Chronic Wounds market in the coming years.

  • Galnobax, by Novalead Pharma, has completed a global Phase I/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both safety and efficacy. The company is investigating it in the Phase III clinical trial.

Get an overview of pipeline landscape @ Chronic Wounds Clinical Trials Analysis 

A chronic wound is a wound that does not heal in an orderly set of stages and in a predictable amount of time the way most wounds do; wounds that do not heal within three months are often considered chronic.

Chronic Wounds Emerging Drugs

 

  • Galnobax by Novalead Pharma

 

Galnobax, by Novalead Pharma, is a topical gel of Esmolol hydrochloride for the treatment of hard to heal diabetic foot ulcers. It is a repurposed generic drug molecule, which has completed a global Phase I/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both safety and efficacy.

 

  • Engensis by ViroMed BioPharma

 

Engensis(VM202) is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms needed for optimal therapeutic benefits.

 

  • ON101 by Oneness Biotech

 

Oneness Biotech is also coming up with its new botanical drug ointment, ON101. Clinical studies demonstrated that ON101 has significant therapeutic effects on wound healing and could reduce scar formation. 

 

  • TTAX01 by Tissue Tech

 

One Pharma Company named Tissue Tech, which is developing a product TTAX01 for the management of venous leg ulcers and non healing wounds. 

 

  • EscharEx by MediWound 

 

Another topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds is being developed by MediWound, named EscharEx. It is a mixture of proteolytic enzymes for the management of debridement in chronic and other hard-to-heal wounds

 

Scope of Chronic Wounds Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Anterogen, ViroMed BioPharma, Novalead Pharma, Oneness Biotech, MediWound, Tissue Tech/Amniox Medical, Charsire Biotechnology, Energenesis Biomedical, and others.

  • Pipeline Therapies:  ALLO-ASC-DFU, Engensis, Galnobax, ON101, EscharEx, TTAX01, CSTC1, ENERGI-F703, and others.

Table of Contents:

1

Chronic Wounds Report Introduction

2

Chronic Wounds Executive Summary

3

Chronic Wounds Overview

4

Chronic Wounds- Analytical Perspective In-depth Commercial Assessment

5

Chronic Wounds Pipeline Therapeutics

6

Chronic Wounds Late Stage Products (Phase II/III)

7

Chronic Wounds Mid Stage Products (Phase II)

8

Chronic Wounds Early Stage Products (Phase I)

9

Chronic Wounds Preclinical Stage Products

10

Chronic Wounds Therapeutics Assessment

11

Chronic Wounds Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Chronic Wounds Key Companies

14

Chronic Wounds Key Products

15

Chronic Wounds Unmet Needs

16 

Chronic Wounds Market Drivers and Barriers

17

Chronic Wounds Future Perspectives and Conclusion

18

Chronic Wounds Analyst Views

19

Appendix

20

About DelveInsight

Related Reports:

Chronic Wounds Market

DelveInsight’s Chronic Wounds – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Wounds Epidemiology

DelveInsight’s Chronic Wounds – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Chronic Wounds epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/